Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Medivation Presents Positive New Data On Dimebons Long-term Efficacy and Novel Mechanism of Action At the International Conference On Alzheimers Disease
August 23rd, 2008
ALZHEIMER'S DISEASE Medivation, Inc. (NASDAQ: MDVN) announced new data showing that its investigational drug Dimebon continues to produce broad, clinically meaningful benefits in Alzheimer's disease patients after long-term dosing, and appears to operate through a novel mechanism of action. These data were presented today in a podium session and two poster sessions at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago. The presentations are highlighted below. New data from a six-month open-label extension of the 12-month placebo-controlled study of Dimebon in patients with...
Source: Law & Health Weekly (2008-08-23)
|
